Key takeaways
- Insight into guideline recommendations for NT-proBNP in heart failure evaluation and management
- Practical understanding of how NT-proBNP supports earlier diagnosis and risk stratification in high-risk and comorbid patients
- Strategies for integrating NT-proBNP testing with standard assessments to enhance patient monitoring, management, and resource optimization
Catching Heart Failure Early: The Power of NT-proBNP in Clinical Practice (39:59)
Heart failure affects millions of patients, yet early diagnosis remains a persistent challenge. In this session, hear from Neil Skolnik, MD; Ileana Piña, MD; and Nishant Shah, MD as they review the clinical evidence behind NT-proBNP and demonstrate how this guideline-recommended biomarker is being applied in real-world care to support more informed, timely decision-making.
Contact Us
Do you have questions about our products or services? We’re here to help. Contact a Roche representative in your region.
The role of NT-proBNP testing (8:07)
Overview of the role of natriuretic peptides (NT-proBNP) testing in early heart failure detection and guideline recommendations to evaluate non-specific dyspnea.
Early diagnosis of heart failure (7:20)
Explains how team-based care allows clinicians to detect subclinical (Stage B) HF before symptomatic stages.
Risks and evidence (10:37)
Links hypertension, diabetes, and obesity with heart failure. Real world evidence showing actionable improvement in HF outcomes.
Evaulation and management (6:47)
Lays out a step-by-step algorithm to shift the diagnostic approach and offering therapeutic alternatives.
Key points (2:58)
The shift from reactive care to early, proactive heart failure detection.
